Core Insights - The FDA has provided constructive feedback on Seres Therapeutics' SER-155 development plans, supporting a Phase 2 study with a primary efficacy endpoint focused on reducing bloodstream infections (BSIs) post-allo-HSCT [1][2][4] - Seres Therapeutics plans to submit a proposed protocol for the next SER-155 study to the FDA in Q2 2025, incorporating the agency's feedback [1][2] - SER-155 has shown a 77% relative risk reduction in BSIs in a Phase 1b study, along with reduced systemic antibiotic exposure and lower incidence of febrile neutropenia [2][4] Company Overview - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving outcomes for medically vulnerable populations [5] - The company has received Breakthrough Therapy designation for SER-155, targeting the reduction of BSIs in allo-HSCT patients, and Fast Track designation for reducing infection risk and graft-versus-host disease [5][4] - SER-155 is designed to decolonize gastrointestinal pathogens and improve immune tolerance in patients undergoing allo-HSCT for hematological malignancies [3][5] Future Development Plans - The next study design for SER-155 may retain elements from the previous Phase 1b trial, which demonstrated significant clinical benefits [2][4] - The company is actively seeking partnerships to support the further development of SER-155 in allo-HSCT [2]

HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of developme ...

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second $5 million tranche of its previously announced $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clini ...

Core Viewpoint - Serina Therapeutics has successfully closed the second tranche of a $10 million equity financing, enabling the advancement of its investigational drug SER-252 into Phase 1 clinical trials for advanced Parkinson's disease patients in the second half of 2025 [1][3]. Financing Details - The second tranche involved a $5 million investment from strategic shareholder JuvVentures, with Serina issuing 500,000 shares at $10 per share, reflecting a 113% premium over the closing price on January 31, 2025 [2]. - Additionally, warrants for up to 755,728 shares at an exercise price of $18.00 per share were issued to JuvVentures [2]. Product Development - SER-252 (POZ-apomorphine) is designed to provide continuous dopaminergic stimulation (CDS), which can reduce levodopa-related motor complications in advanced Parkinson's patients [4]. - The drug leverages Enable Injections' enFuse™ wearable drug delivery platform for enhanced patient comfort and convenience [4]. Technology Overview - Serina's proprietary POZ Platform™ utilizes a synthetic polymer to improve drug loading control and release precision, aiming to maintain stable blood levels of therapeutic agents [5]. - The POZ technology has potential applications across various drug delivery formulations, including a non-exclusive license agreement with Pfizer for lipid nanoparticle drug delivery [6]. Company Background - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases, utilizing its POZ Platform™ to enhance the efficacy and safety profiles of various therapeutic modalities [7].

- Transaction eliminates $11.2 million in debt, strengthening financial position - HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the sale of its UniverXome subsidiary. The transaction was finalized on December 23, 2024 and eliminated $11.2 million in associated subsidiary-level debt, positioning Serina with a debt-free balance ...

Board of Directors Update - Karen J Wilson appointed to the Board of Directors bringing over three decades of leadership experience in the life sciences sector [1][3] - Steven Mintz departed from the Board of Directors after contributing to the company's transition from private to public [4] POZ Platform Technology - Proprietary POZ technology based on poly(2-oxazoline) polymer enables greater control in drug loading and precision in drug release rate [5] - POZ technology aims to improve pharmacokinetic profiles of drugs with narrow therapeutic windows [5] - Potential applications across a broad range of payloads and indications with ongoing out-licensing and partnership arrangements including a non-exclusive license agreement with Pfizer [6] Company Overview - Clinical-stage biotechnology company developing wholly owned drug product candidates for neurological diseases and other indications [7] - POZ Platform technology has potential to improve efficacy and safety profiles of small molecules RNA-based therapeutics and antibody-based drug conjugates [7] - Headquarters located in Huntsville Alabama on the campus of the HudsonAlpha Institute of Biotechnology [7]

Meet with Serina's CEO Steven A. LedgerParkinson's disease is a progressive neurological disorder that primarily affects movementContinuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson's patientsDiscussion of the Serina IND candidate's target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage bi ...

Core Viewpoint - Serina Therapeutics is advancing its proprietary POZ Platform drug delivery technology aimed at improving treatment for Parkinson's disease through continuous dopaminergic stimulation (CDS) [1][4]. Company Overview - Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases and other indications [4]. - The company is headquartered in Huntsville, Alabama, on the campus of the HudsonAlpha Institute of Biotechnology [4]. Upcoming Event - CEO Steven A. Ledger will present at Tribe Public's webinar titled "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on December 18, 2024 [1]. - The event will allow participants to submit questions to the CEO, enhancing engagement with stakeholders [3]. Technology and Product Development - Serina's POZ Platform aims to enhance the efficacy and safety profiles of various therapeutic modalities, including small molecules, RNA-based therapeutics, and antibody-drug conjugates (ADCs) [4].

HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response t ...

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with strategic shareholder JuvVentures (UK) Limited. The transaction provides Serina with funding to continue advancing SER-252 (POZ-apomorphine), enabled by its proprietary POZ Platform™ drug optimization technology, into a Phase 1 clinical trial in advanced Parkinson's disease patients in the second half of 2025. Und ...